CGTBiologicstaleBeijing BiotechPhase 2
MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))
Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)
#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING